Technical Analysis for PRAX - Praxis Precision Medicines, Inc.

Grade Last Price % Change Price Change
C 56.45 4.17% 2.26
PRAX closed up 4.17 percent on Friday, January 22, 2021, on 23 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Down
Historical PRAX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Fell Below 20 DMA Bearish 4.17%
1,2,3 Pullback Bullish Bullish Swing Setup 4.17%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.17%
Outside Day Range Expansion 4.17%
20 DMA Support Bullish -0.65%
1,2,3 Pullback Bullish Bullish Swing Setup -0.65%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.65%
Older End-of-Day Signals for PRAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Praxis Precision Medicines, Inc. Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cooper Neuroscience Nervous System Disorders Central Nervous System Disorders Precision Medicine Epilepsy Depressive Disorder Major Depressive Disorder Depression Oligonucleotide Huntington's Disease Neuron Spinal Muscular Atrophy Treatment Of Major Depressive Disorder Antisense RNA Receptor Positive Essential Tremor Ionis

Is PRAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 60.95
52 Week Low 23.9001
Average Volume 308,118
200-Day Moving Average 0.00
50-Day Moving Average 46.36
20-Day Moving Average 56.02
10-Day Moving Average 57.53
Average True Range 3.92
ADX 31.34
+DI 17.68
-DI 16.51
Chandelier Exit (Long, 3 ATRs ) 49.20
Chandelier Exit (Short, 3 ATRs ) 55.27
Upper Bollinger Band 61.81
Lower Bollinger Band 50.23
Percent B (%b) 0.54
BandWidth 20.67
MACD Line 2.92
MACD Signal Line 3.75
MACD Histogram -0.8344
Fundamentals Value
Market Cap 2.16 Billion
Num Shares 38.3 Million
Price-to-Sales 0.00
Price-to-Book 95.89
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.05
Resistance 3 (R3) 61.51 59.11 61.11
Resistance 2 (R2) 59.11 57.69 59.38 60.80
Resistance 1 (R1) 57.78 56.80 58.45 58.32 60.49
Pivot Point 55.38 55.38 55.71 55.65 55.38
Support 1 (S1) 54.05 53.96 54.72 54.59 52.41
Support 2 (S2) 51.65 53.07 51.92 52.10
Support 3 (S3) 50.32 51.65 51.79
Support 4 (S4) 50.86